CDSCO drug approval process: How clinical trials test medicines phase by phase
Thousands of experimental compounds enter clinical testing, but only a small fraction clear every stage to gain regulatory approval.
How clinical trials test new drugs
Developing a new medicine and bringing it to market requires years of rigorous testing under strict oversight from regulatory authorities such as India's Central Drugs Standard Control Organisation (CDSCO). Before any experimental molecule is administered to human subjects, extensive laboratory assays and animal studies evaluate its basic biological activity and safety profile.
Once a drug candidate progresses to human clinical trials, it must clear three sequential phases before regulators will evaluate it for public prescription. Each phase is constructed to answer specific scientific questions, gradually expanding the trial population while evaluating both safety and efficacy.
| Trial phase | Participant group | Primary objective | Typical success rate |
|---|---|---|---|
| Phase 1 | 20–100 healthy volunteers | Safety and dosage limits | ~70% |
| Phase 2 | 100–300 patient volunteers | Efficacy and side effects | ~33% |
| Phase 3 | 1,000–3,000 patients | Comparative trial against standard treatments | ~25–30% |
| Phase 4 | Post-approval patient population | Long-term monitoring | Ongoing |
Why drugs pass Phase 1 but fail later stages
Phase 1 trials focus primarily on basic safety and human pharmacology rather than determining whether the medicine cures the condition. A small group of healthy volunteers receives low doses to help clinical researchers understand how the human body absorbs, metabolises, and excretes the compound, as well as to identify obvious toxic effects. Because healthy organ systems clear compounds predictably, a drug frequently passes Phase 1 by demonstrating tolerable safety at therapeutic doses.
Failure rates rise significantly when drugs enter Phase 2. At this point, the experimental treatment is given to patients who suffer from the targeted medical condition. Many compounds that performed effectively in cellular models or animal studies fail to show therapeutic benefit in human patients. Others trigger unexpected adverse reactions when introduced to diseased tissue or compromised physiological systems.
The final regulatory hurdle in Phase 3
Phase 3 represents the largest and most costly stage of evaluation. Clinical trial networks evaluate the medicine in thousands of patients across diverse hospital sites to establish statistically robust proof of effectiveness and identify rare adverse events.
A drug candidate can pass Phase 2 in a small, relatively uniform patient cohort but still fail Phase 3. Larger trial cohorts introduce broader genetic diversity, varying disease severity, and potential interactions with other common medications. Furthermore, Phase 3 trials typically evaluate the candidate against existing standard therapies. If a new medicine demonstrates safety but offers no performance advantage over treatments already available in India, regulatory approval may be withheld.
Post-market surveillance in Phase 4
Securing formal CDSCO approval does not mark the end of clinical evaluation. Phase 4 post-marketing surveillance tracks long-term safety profiles across the wider population. Systems such as the Pharmacovigilance Programme of India monitor reported side effects from health facilities nationwide, ensuring ongoing safety while supporting high regulatory standards across the domestic pharmaceutical industry.
Key numbers
| What | Figure | Source |
|---|---|---|
| Phase 1 trial success rate | Approximately 70% | General pharmaceutical research industry statistics |
| Phase 2 trial success rate | Approximately 33% | General pharmaceutical research industry statistics |
| Phase 3 trial success rate | Approximately 25-30% | General pharmaceutical research industry statistics |
Questions readers are asking
Why do most experimental drugs fail in Phase 2?
Phase 2 is the first time an experimental drug is tested on actual patients rather than healthy volunteers. Many compounds fail here because they do not demonstrate sufficient therapeutic efficacy or cause unacceptable side effects in diseased tissue.
What is the role of CDSCO in drug trials in India?
The Central Drugs Standard Control Organisation (CDSCO) evaluates trial protocols, grants permission for clinical trials to proceed across phases, and reviews final safety and efficacy data before authorizing a new medicine for public market access.
In this story
| Name | Role in the story |
|---|---|
| Central Drugs Standard Control Organisation | India's national regulatory body responsible for approving clinical trials and new pharmaceutical products. |



